Outsourced revenue cycle management for hospitals and health systems
Conifer Health Solutions runs revenue cycle operations for health systems, built on Epic, GE Centricity and InterSystems IRIS alongside a .NET, React and Kubernetes engineering core. Its BI layer spans Power BI, Microsoft Fabric, MicroStrategy and BusinessObjects, while AS/400 and Microsoft Access persist, pointing to legacy consolidation work. Accelerating hiring is overwhelmingly healthcare operations staff at mid level, focused on patient access and collections.
Notable leadership hires: Patient Access Director
Conifer Health Solutions is a Frisco, Texas-based company providing revenue cycle management and value-based care services to health systems, hospitals, physician groups and employers. Its services cover patient access, insurance eligibility, medical billing, collections, AR management and Epic EHR implementation. Founded in 2008 and privately held, the company employs more than 10,000 people. Current hiring is concentrated in the United States.
Conifer uses Epic, GE Centricity and InterSystems IRIS for clinical data, .NET, React and Angular for applications, Kubernetes, Docker and Azure DevOps for delivery, and Power BI, Microsoft Fabric and BigQuery for analytics.
Yes. Hiring is accelerating and centered on healthcare revenue cycle roles such as patient access, mostly at mid level, with a Patient Access Director among leadership openings. All hiring is in the United States.
Conifer Health Solutions is headquartered in Frisco, Texas, United States, and has more than 10,000 employees.
Other companies in the same industry, closest in size
Conifer Health Solutions's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.